MEDIFAST INC
$ 12.09
-4.20%
10 Aug - close price
- Market Cap 135,175,000 USD
- Current Price $ 12.09
- High / Low $ 12.78 / 12.00
- Stock P/E N/A
- Book Value 18.99
- EPS -2.33
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.12 %
- 52 Week High 14.67
- 52 Week Low 9.22
About
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Analyst Target Price
$12.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-04 | 2026-02-17 | 2025-11-03 | 2025-08-04 | 2025-04-28 | 2025-02-18 | 2024-11-04 | 2024-08-05 | 2024-04-29 | 2024-02-20 | 2023-11-06 |
| Reported EPS | -0.28 | -0.19 | -1.65 | -0.21 | 0.22 | -0.07 | 0.1 | 0.35 | 0.92 | 0.66 | 0.55 | 2.12 |
| Estimated EPS | -0.67 | -0.52 | -0.45 | -0.36 | -0.19 | -0.25 | 0.2424 | -0.28 | 0.39 | 0.8 | 0.96 | 1.07 |
| Surprise | 0.39 | 0.33 | -1.2 | 0.15 | 0.41 | 0.18 | -0.1424 | 0.63 | 0.53 | -0.14 | -0.41 | 1.05 |
| Surprise Percentage | 58.209% | 63.4615% | -266.6667% | 41.6667% | 215.7895% | 72% | -58.7459% | 225% | 135.8974% | -17.5% | -42.7083% | 98.1308% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Nov 2023 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2023-11-07 | None | None | None | None | None | None | None | None | None |
| Amount | $1.65 | $1.65 | $1.65 | $1.64 | $1.64 | $1.64 | $1.64 | $1.42 | $1.42 | $1.42 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MED
2026-08-11 20:21:00
Medifast (MED) reported Q2 CY2026 results that exceeded Wall Street expectations for revenue and EPS, driven by improved coach productivity and the new Trilivy brand. The company reconfirmed its full-year revenue guidance and provided positive EPS guidance. Analysts focused on the Catalyst program's cost savings, the path to profitability, coach reception to Trilivy, and future margin trajectory during the earnings call.
2026-08-10 08:40:57
Medifast's Q2 earnings surpassed analyst expectations, driven by improved coach productivity and the new Trilivy brand. The company reconfirmed its full-year revenue and EPS guidance. Analysts focused on the Catalyst program's costs and profitability impact, coach reception to Trilivy, and future margin trajectory.
2026-08-08 08:11:53
Medifast (MED) is launching its new Trilivy metabolic-health platform and implementing further cost reductions through its Catalyst program, aiming for a return to profitability in Q4 2026. While Q2 2026 revenues fell year-over-year, they still beat estimates, and coach productivity has shown improvement. The company faces ongoing challenges with shrinking coach numbers and projected losses before Q4, making the turnaround dependent on Trilivy's success, revenue stability, and effective cost savings.
2026-08-08 08:11:53
Medifast (MED) shares have risen 13.6% in the past month, outperforming the industry, driven by narrower-than-expected Q2 2026 losses and improving coach productivity. While revenue and the active coach base remain under pressure, management expects continued productivity gains and has maintained full-year revenue guidance, suggesting potential for sustained momentum despite a mixed operational backdrop.
2026-08-07 18:11:11
Medifast (MED) presents a challenging investment scenario with a low forward sales valuation compared to its industry, but faces significant headwinds including declining revenues, a shrinking coach network, and ongoing losses. Despite these challenges, the company's strong balance sheet provides a cushion for its Trilivy-led turnaround efforts, which have shown early signs of improved coach productivity. The success of this turnaround hinges on Medifast's ability to drive client acquisition, grow its coach network, and ultimately return to profitability, with management targeting this goal by Q4 2026.
2026-08-07 18:11:10
Medifast (MED) shares have rallied 13.6% in the past month, outperforming the industry's growth, driven by improving coach productivity and narrowing earnings loss. Despite this, the company still faces challenges with a shrinking coach base and mixed Style Scores, indicating that sustained momentum will depend on continued productivity gains, firmer revenues, and progress toward profitability.
